We have completed that phase I/II study of cisplatin, paclitaxel, and cytoxan for newly diagnosed advanced stage disease. Data to date indicate that in patients with >3cm residual at the initiation of chemotherapy, this regimen is 3-4 times better than any regimen previously reported. In such patients who receive paclitaxel at 250 mg/m2/cycle, relapse free survival is 85% at l yr and 69% at 2 yrs. This compares with previous reports of approximately 30% overall l yr survival in such patients. A multiinstitutional phase II study is planned to confirm these exciting resu s.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CM006540-02
Application #
2571486
Study Section
Special Emphasis Panel (CPB)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Division of Cancer Treatment
Department
Type
DUNS #
City
State
Country
United States
Zip Code